Overview
The system is a practical prototype that improves LLM-based trial predictions on a tiny sample and shows useful tool integration; it needs larger, transparent evaluations and reduced reliance on closed LLM APIs before production use.
Citations3
Evidence Strength0.40
Confidence0.70
Risk Signals10
Trust Signals
Findings with numeric evidence: 4/4
Findings with evidence refs: 4/4
Results with explicit delta: 3/3
Reproducibility
Status: Partial assets available
Open source: Partial
At A Glance
Cost impact: 50%
Production readiness: 40%
Novelty: 60%
Why It Matters For Business
ClinicalAgent shows a practical path to combine LLM reasoning and domain databases to flag risky trials and estimate enrollment, speeding early-stage decisions; validate on larger data before clinical use.
Who Should Care
Summary TLDR
ClinicalAgent is a system that turns GPT-4 into a team of specialist agents (planning, efficacy, safety, enrollment) that call external databases (DrugBank, Hetionet, ClinicalTrials.gov) and predictive models to assess clinical trials. On a small benchmark (40 train / 40 test samples) it reached ROC-AUC 0.8347 and PR-AUC 0.7908, improving PR-AUC by 0.3326 over direct GPT prompting. The design shows how function-calling and stepwise reasoning (Least-to-Most, ReAct) can make LLM outputs more actionable, but the evaluation is small and depends on closed-source LLM APIs.
Problem Statement
Make LLMs useful for clinical trial tasks by combining GPT-4, stepwise reasoning, external biomedical databases, and specialist predictive models so the system can predict trial outcomes, enrollment difficulty, safety, and efficacy with explainable steps.
Main Contribution
ClinicalAgent: a multi-agent framework that delegates trial tasks to specialist agents and aggregates their outputs for explainable decisions.
Integration of tool calls (DrugBank, Hetionet, ClinicalTrials.gov) and small predictive models (enrollment, drug/disease risk) into LLM reasoning.
Key Findings
ClinicalAgent raised precision-recall performance over direct GPT prompting.
ClinicalAgent matched or exceeded classical ML on ROC-AUC in this test.
Results
| Metric | Value | Baseline | Delta | Split / Dataset | Evidence | Evidence Ref |
|---|---|---|---|---|---|---|
| PR-AUC | 0.7908 | GPT-4 standard prompt 0.4582 | +0.3326 | 40 test samples from clinical trial outcome benchmark | Table 2 shows ClinicalAgent PR-AUC 0.7908 vs GPT-4 0.4582 | Table 2 |
| ROC-AUC | 0.8347 | GBDT 0.8 | +0.0347 | 40 test samples from clinical trial outcome benchmark | Table 2 lists ClinicalAgent ROC-AUC 0.8347, GBDT 0.8 | Table 2 |
What To Try In 7 Days
Prototype a simple agent pipeline: planning + one specialist (enrollment) using GPT-4 function calls.
Hook a single database (DrugBank or ClinicalTrials.gov) via a function-call wrapper and test retrieval accuracy.
Add a few-shot decomposition prompt and compare PR-AUC vs direct GPT prompts on a small held-out set.
Agent Features
Memory
Planning
Tool Use
Frameworks
Is Agentic
Yes
Architectures
Collaboration
Reproducibility
Risks & Boundaries
Limitations
Evaluation used only 40 training and 40 test samples, limiting statistical confidence.
Relies on closed-source GPT-4 API; behaviour and costs depend on external provider.
When Not To Use
For high-stakes, regulatory decisions without human clinical review.
When full patient-data privacy forbids external API calls.
Failure Modes
Incorrect or missing database lookups leading to wrong conclusions.
LLM hallucinations despite tool calls, especially for rare drugs/diseases.